Pancreatic cancer: updated data on daraxonrasib with chemotherapy
An early-phase study in 61 patients showed responses, but confirmation in a randomised comparison is needed.

Updated results for daraxonrasib combined with chemotherapy in patients with metastatic pancreatic adenocarcinoma were presented on 20 November at the EORTC–NCI–AACR symposium in Barcelona. The reported cohort of the phase I/II RMC-GI-102 study concerns patients who had received no previous treatment for their metastatic disease. The medicine was given with gemcitabine and nab-paclitaxel, rather than on its own.
The updated analysis includes 61 patients, with a data cutoff of 28 September 2026 and median follow-up of 18.3 months. An objective response was recorded in 60.7%, including complete responses in 8.2%. In a complete response, tumours were no longer detectable on examinations; this does not establish a lasting cure.
Median progression-free survival was 12.8 months. This measure differs from overall survival. Because the study did not compare participants with a group receiving chemotherapy alone, it does not by itself prove that the combination is superior to standard treatment.
According to the symposium announcement, common adverse effects included rash, diarrhoea, fatigue and a reduction in certain blood cells. Treatment discontinuation because of adverse effects related to daraxonrasib was recorded in 5% of patients.
The combination is being evaluated in the ongoing randomised phase III RASolute 303 trial, with comparison against chemotherapy. The new data concern research into first-line treatment and do not constitute a new approval of this regimen. RMC-GI-102 was sponsored by Revolution Medicines.
English translation of the Greek edition · Read in Greek